XOMA - XOMA Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
17.56
-0.19 (-1.07%)
As of 12:36PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close17.15
Open17.99
Bid17.55 x 800
Ask17.76 x 800
Day's Range17.25 - 18.19
52 Week Range11.02 - 20.29
Volume40,792
Avg. Volume80,020
Market Cap153.199M
Beta (3Y Monthly)0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.90
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.00
Trade prices are not sourced from all markets
  • Health Check: How Prudently Does XOMA (NASDAQ:XOMA) Use Debt?
    Simply Wall St.

    Health Check: How Prudently Does XOMA (NASDAQ:XOMA) Use Debt?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • GlobeNewswire

    XOMA’s Royalty Portfolio Expands Significantly

    XOMA Corporation (XOMA), today announced its portfolio of potential future royalty and milestone payments has significantly increased with the addition of Janssen Biotech, Inc. drug candidates for which XOMA could receive future milestone and royalty payments. In addition, Janssen has elected to accelerate its base annual license fee obligation and will make a one-time $2.5 million payment to XOMA. For each program, XOMA is entitled to receive milestone payments upon the achievement of certain clinical development and regulatory approval events.

  • Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Xoma (XOMA) Reports Q2 Loss, Tops Revenue Estimates

    Xoma (XOMA) delivered earnings and revenue surprises of 14.55% and 52.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    XOMA Reports Second Quarter 2019 Royalty Asset Portfolio Highlights and Financial Results

    Novartis’s iscalimab highlighted at key scientific conferences First patient dosed with gevokizumab in collaborator clinical study Sesen Bio announced intention to initiate.

  • A Firm's First Profit Can Mean Big Returns for Investors
    Zacks

    A Firm's First Profit Can Mean Big Returns for Investors

    A Firm's First Profit Can Mean Big Returns for Investors

  • Analysts Estimate Xoma (XOMA) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Xoma (XOMA) to Report a Decline in Earnings: What to Look Out for

    Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    XOMA to Present at the 2019 Wedbush PacGrow Healthcare Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the 2019 Wedbush PacGrow Healthcare Conference in New York, New York.  The presentation will take place on Wednesday, August 14, 2019, at 3:40PM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com or by clicking http://wsw.com/webcast/wedbush35/xoma/.  An archived version of the webcast will be available for 90 days after the event. EXPLANATORY NOTE: All references to “portfolio” in this press release are to milestone and/or royalty rights associated with drug products in development.  All references to “assets” in this presentation are to milestone and/or royalty rights associated with individual drug products in development.

  • What Kind Of Share Price Volatility Should You Expect For XOMA Corporation (NASDAQ:XOMA)?
    Simply Wall St.

    What Kind Of Share Price Volatility Should You Expect For XOMA Corporation (NASDAQ:XOMA)?

    Anyone researching XOMA Corporation (NASDAQ:XOMA) might want to consider the historical volatility of the share price...

  • GlobeNewswire

    First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma

    XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding.  For more information, visit www.xoma.com.

  • If You Had Bought XOMA (NASDAQ:XOMA) Stock Five Years Ago, You'd Be Sitting On A 81% Loss, Today
    Simply Wall St.

    If You Had Bought XOMA (NASDAQ:XOMA) Stock Five Years Ago, You'd Be Sitting On A 81% Loss, Today

    XOMA Corporation (NASDAQ:XOMA) shareholders should be happy to see the share price up 17% in the last month. But will...

  • Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates
    Zacks

    Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates

    Xoma (XOMA) delivered earnings and revenue surprises of 261.54% and 152.12%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press

    Xoma: 1Q Earnings Snapshot

    The Emeryville, California-based company said it had net income of 21 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire

    XOMA Reports First Quarter 2019 Financial Results and Operating Highlights

    Acquired rights to potential milestone and royalty payments associated with five hematology assetsReceived $5.5 million milestone paymentAdded Barbara Kosacz to XOMA’s Board of.

  • Will Xoma (XOMA) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will Xoma (XOMA) Report Negative Q1 Earnings? What You Should Know

    Xoma (XOMA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Portland biotech inks $9M+ deal for drug royalties
    American City Business Journals

    Portland biotech inks $9M+ deal for drug royalties

    Xoma will pay Aronora up front to help it continue to develop its drug therapies for blood clots, in exchange for a share of potential income down the road.

  • Is XOMA Corporation's (NASDAQ:XOMA) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.

    Is XOMA Corporation's (NASDAQ:XOMA) Balance Sheet Strong Enough To Weather A Storm?

    While small-cap stocks, such as XOMA Corporation (NASDAQ:XOMA) with its market cap of US$116m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a down...

  • GlobeNewswire

    XOMA Acquires Royalty Rights to Five Hematology Candidates

    EMERYVILLE, Calif., April 08, 2019 -- XOMA Corporation (NASDAQ: XOMA) announced today it has agreed to acquire the rights to potential royalty payments and a portion of the.

  • GlobeNewswire

    XOMA to Present at the 2019 H.C. Wainwright Global Life Sciences Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the 2019 H.C. Wainwright Global Life Sciences in London, United Kingdom.  The presentation will take place on Tuesday, April 9, 2019, at 11:50AM BST (6:50 AM ET), and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com.  An archived version of the webcast will be available for 90 days after the event. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future.  For more information, visit www.xoma.com.

  • GlobeNewswire

    XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights

    Added seven new partner-funded programs in 2018 with potential for milestone and royalty paymentsCurrent cash balance sufficient to fund operations for multiple years.

  • GlobeNewswire

    XOMA to Present at the Cowen and Company 39th Annual Health Care Conference

    XOMA Corporation (XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the company’s business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts.  The presentation will take place on Tuesday, March 12, 2019, at 12:00PM ET, and can be accessed via a live webcast on the investor relations page of XOMA’s website at www.xoma.com.  An archived version of the webcast will be available for 90 days after the event. XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas.  Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics.  The Company’s royalty-aggregator business model includes acquiring additional licenses to partner-funded programs.  XOMA’s license portfolio has the potential to generate significant milestone payments and royalty revenue in the future.  For more information, visit www.xoma.com.

  • GlobeNewswire

    XOMA Receives $5.5 Million Payment from Rezolute

    XOMA Corporation (XOMA) announced today it has received a $5.5 million payment from Rezolute, Inc., related to the Companies’ 2017 license agreement, as most recently amended on January 7, 2019. “Our business model is fundamentally designed to generate significant long-term royalty-based revenue as the underlying assets are commercialized.  Moreover, many of our license agreements include the potential for XOMA to receive significant milestone payments as the licensed assets progress.  The receipt of this milestone payment is a good example of XOMA further strengthening its balance sheet with additional non-dilutive capital.  This capital can be deployed to further expand our portfolio of assets from which we have the potential to earn future milestone payments and royalties,” commented Jim Neal, Chief Executive Officer at XOMA.

  • How Much Are XOMA Corporation (NASDAQ:XOMA) Insiders Spending On Buying Shares?
    Simply Wall St.

    How Much Are XOMA Corporation (NASDAQ:XOMA) Insiders Spending On Buying Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many times Read More...

  • GlobeNewswire

    XOMA Announces Barbara Kosacz Joins its Board of Directors

    EMERYVILLE, Calif., Jan. 03, 2019 -- XOMA Corporation (NASDAQ: XOMA) announced today Barbara Kosacz, a Partner at Cooley LLP, has joined the Company’s Board of Directors.  Ms..

  • GlobeNewswire

    XOMA Announces Closing of Rights Offering

    The Rights Offering was made pursuant to the Company’s effective shelf registration statement on file with the Securities and Exchange Commission (“SEC”) and a prospectus supplement and accompanying prospectus filed with the SEC on November 19, 2018.  XOMA has engaged D.F. King & Co., Inc., to act as information agent with respect to the Rights Offering. For questions regarding the Rights Offering, or to obtain copies of the Rights Offering prospectus and any related materials, please contact D.F. King & Co. at xoma@dfking.com or by telephone at +1 866-721-1324.

  • GlobeNewswire

    XOMA Announces Commencement of Rights Offering

    EMERYVILLE, Calif., Nov. 19, 2018 -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to.